Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials

doi:10.1007/s00432-009-0615-3

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
	Guo, TK; Hao, XY; Ma, B; Yang, KH; Li, YP; Li, HL; Gu, YH; Cai, H; Liu, YL; Li, Y
刊名	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
	2009-12
卷号	135 期号:12 页码:1685-1692
关键词	Hepatocellular carcinoma Octreotide Liver disease Meta-analysis
ISSN号	0171-5216
DOI	10.1007/s00432-009-0615-3
文献子类	Article
英文摘要	To evaluate the effectiveness of octreotide in advanced hepatocellular carcinoma participants on the basis of randomized controlled trials. We searched the Cochrane Center Register of Controlled Trials in The Cochrane Library, PubMed, EMBASE, Chinese Biomedical Literature Database, China Journal Full-text Database, Chinese Scientific Journals Database up to June 2008 in any language. Randomized controlled trials of octreotide for advanced hepatocellular carcinoma were selected and evaluated by two investigators. Any disagreement was solved by discussion. Analyses were performed using Review Manager 4.2. Six randomized controlled trials totaling 352 participants were included. The median survival time was reported in four randomized controlled trials. The results between the octreotide group and the control group (the placebo or best supportive care group) were as follows: 13.0 versus 4.0 months, 1.93 versus 1.97 months, 4.7 versus 5.3 months, and 7.0 versus 2.5 months. Three randomized controlled trials reported 6-month survival rates and 12-month survival rates and meta-analysis results in these two outcomes [(RR 1.35, 95% CI 0.92-1.97); (RR 1.35, 95% CI 0.66-11.16) respectively] were not found to be statistically significant by random-effects model. When we analyzed 6-month survival rates by fixed-effect model (RR 1.30, 95% CI 1.02-1.66), meta-analysis result reached statistical significance. As for the limitations of the included trials, the result may not demonstrate a significant superiority of octreotide administration in participants with advanced hepatocellular carcinoma from the available evidence.
学科主题	Oncology
出版地	NEW YORK
语种	英语
WOS记录号	WOS:000270176900006
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121421]
专题	基础医学院_期刊论文
通讯作者	Yang, KH (reprint author), Lanzhou Univ, Evidence Based Med Ctr, Dong Gang W Rd 199, Lanzhou 730000, Gansu, Peoples R China.
推荐引用方式 GB/T 7714	Guo, TK,Hao, XY,Ma, B,et al. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2009,135(12):1685-1692.
APA	Guo, TK.,Hao, XY.,Ma, B.,Yang, KH.,Li, YP.,...&Yang, KH .(2009).Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,135(12),1685-1692.
MLA	Guo, TK,et al."Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 135.12(2009):1685-1692.